Lucknow

UP Govt to start 'Ekikrit Nikshay Diwas' campaign to diagnose multiple diseases

The campaign will be held on the 15th of each month.

Jatin Shewaramani

The Uttar Pradesh government has now launched a statewide campaign for the diagnosis and treatment of multiple diseases including tuberculosis, filariasis, malaria, chikungunya, kala azar and leprosy.

Notably, the campaign which is known as the "Ekikrit Nikshay Diwas (END)" will be held on the 15th of each month. Under the campaign, government-run healthcare bodies of various UP districts including Lucknow and Kanpur will work on the screening of individuals for multiple ailments and will further provide treatment to the unfit patients.

More about the Ekikrit Nikshay Diwas campaign

Previously, the Nikshay Diwas was organised on the same day every month for the screening of TB cases across the state, but the government has now expanded the scope of the campaign.

Under END, the government-run health and wellness centres, primary health centres and district healthcare centres across all the UP cities will provide diagnosis for ailments including filariasis, malaria, chikungunya, kala azar and leprosy will also be targeted alongside TB on the 15th of every month. Furthermore, the district healthcare authorities will also provide treatment to the patients.

The state has a target to eliminate TB by the year 2025, while leprosy, filariasis, malaria, chikungunya by 2030 and kala azar by the end of this year, for which the END campaign has been triggered.

-With inputs from IANS

To get all the latest content, download our mobile application. Available for both iOS & Android devices. 

This weekend in Ahmedabad: 7 new events you can’t miss!

Maharashtra Election Results | Mumbai Traffic Advisory issued for November 23— Plan your route

IIT Bombay to Amity: 5 universities in Mumbai lead at QS World University Rankings - Asia 2025

Diljit Dosanjh's Ekana Concert: Lucknow police issues traffic advisory

Ahmedabad News | IMD forecasts temp drop today, Lotus Park to be developed by AMC & more

SCROLL FOR NEXT